Five Prime Therapeutics

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative therapeutics to improve the lives of patients with serious diseases. Our comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions us to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
Type
Public
HQ
South San Francisco, US
Founded
2001
Employees
154 (est)+26%
Five Prime Therapeutics was founded in 2001 and is headquartered in South San Francisco, US

Key People at Five Prime Therapeutics

Aron Knickerbocker

Aron Knickerbocker

Senior Vice President and Chief Business Officer, Board of Directors
Julie Hambleton

Julie Hambleton

Senior VP, Chief Medical Officer
Jim Blair

Jim Blair

Director
Marc Belsky

Marc Belsky

Senior Vice President and Chief Financial Officer
Gail Maderis

Gail Maderis

President and CEO
Lauretta Cesario

Lauretta Cesario

Vice President, Human Resources

Five Prime Therapeutics Locations

South San Francisco, US

Five Prime Therapeutics Metrics

Five Prime Therapeutics Summary

Market capitalization

$1.6 B

Closing share price

$59.5
Five Prime Therapeutics's latest market capitalization is $1.6 B.

Five Prime Therapeutics Market Value History

Five Prime Therapeutics News

Five Prime Therapeutics Company Life

You may also be interested in